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BACKGROUND: Carcinoma-associated fibroblasts (CAFs) can promote the progression of tumours in many ways. They can remodel
the extracellular matrix to generate an environment that enables the invasion of cancer cells. We hypothesised that compounds that
prevent matrix remodelling by CAFs would block their ability to promote carcinoma cell invasion.
METHODS: We designed a screen for compounds that interfere with CAF-promoted matrix remodelling. Hits from this screen were
investigated in organotypic invasion models of squamous cell carcinoma (SCC).
RESULTS: We find that lovastatin and simvastatin reduce matrix remodelling by fibroblasts and thereby reduce SCC invasion. This class
of compounds exert their effects partly through disrupting the function of Rab proteins, and we show a new role for Rab21 in
promoting cancer cell invasion promoted by CAFs.
CONCLUSIONS: Rab21 is required for CAFs to promote the invasion of cancer cells. It enables the accumulation of integrin a5 at the
plasma membrane and subsequent force-mediated matrix remodelling.
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The local invasion of cancer is a major problem and is frequently
associated with distant metastases. However, cancer cell invasion is
not solely determined by the characteristics of the cancer
cells but also by multiple cell types within tumours, including
fibroblasts and a range of immune cells (Egeblad et al, 2005).
Matrix remodelling by fibroblasts generates paths through the
extracellular matrix (ECM) that are subsequently used by cancer
cells (Gaggioli et al, 2007). This process requires MMPs, integrins
and the actin cytoskeleton (Friedl and Wolf, 2008). In particular,
coordination of integrin-mediated matrix attachment and acto-
myosin force generation enable fibroblasts to move matrix
components such as collagen fibres (Grinnell, 2003; Meshel et al,
2005). This process is regulated at many levels including the
delivery of integrins to the plasma membrane, integrin activation,
actin polymerisation and regulation of myosin activity (Grinnell,
2003). Integrin delivery and recycling is mediated through various
vesicular compartments and is largely controlled by Rab family
small G proteins (Jones et al, 2006; Pellinen and Ivaska, 2006). Both
Rab 5 and Rab 21 have been localised to early endosomes from
which integrins can be recycled back to the plasma membrane by
either Rab4- or Rab11-dependent route (Jones et al, 2006; Pellinen
et al, 2006). Ligand-bound integrins initiate a range of intracellular
signalling pathways, including activation of actomysoin contrac-
tion. Myosin activity is largely controlled by the phosphorylation
of MLC, which can be performed by numerous kinases including
the RhoA-regulated kinases ROCK1 and ROCK2 (Olson and Sahai,
2009). Both ROCK and MLC function are required for matrix
remodelling by fibroblasts (Gaggioli et al, 2007; Honjo et al, 2007;
Yuge et al, 2007).
At a microscopic level matrix remodelling can be visualised by
the appearance of holes in the ECM adjacent to the carcinoma-
associated fibroblasts (CAFs) and the concentration of matrix
fibres around cells. Many fibroblasts also have the ability to
contract collagen gels at the macroscopic level (Ngo et al, 2006).
We noted a good correlation between matrix remodelling at the
microscopic and macroscopic levels and with the ability of CAFs to
promote the invasion of squamous cell carcinoma (SCC) cells. We
therefore hypothesised that matrix contraction by CAFs could be
used as a screening method to identify compounds that prevent
matrix remodelling and hence would reduce fibroblast-stimulated
carcinoma cell invasion.
In this work we screen almost 200 compounds for their effect
on matrix remodelling by CAFs. We find that two HMG-CoA
reductase inhibitors reduce matrix remodelling by fibroblasts and
consequently diminish cancer invasion. This class of compounds
exert their effects partly through disrupting the function of Rab
proteins and we show a new role for Rab21 in matrix remodelling
associated with delivery of integrin a5 to the plasma membrane
and the generation of contractile force.
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sMATERIALS AND METHODS
Cell culture and transfection
Carcinoma-associated fibroblasts and SCC12 were cultured as
described by Gaggioli et al (2007). HN-CAF were transfected with
100nM siRNA using Dharmafect 1 (Dharmacon; catalogue no.
T-2001-03) 2ml per well in six-well plates, Dharmafect 2 (Dharmacon;
catalogue no. T-2002-03) was used for SCC12 siRNA transfection.
Plasmid transfections were performed using Fugene-6. Human Rab11b
a n d2 1c D N A sw e r ef u s e do nt ot h eCt e r m i n u so fm C h e r r ya n dC F P
respectively (details available on request). GFP-Rab5a was a gift from
Sharon Tooze (Cancer Research UK London Research Institute).
The following siRNA reagents from Dharmacon were used:
RabGGTaseb #1, GAGAAUGAGUGGCAUCUAUUU; RabGGTaseb
#2, UUACUUGGCUGGUGGCUUUUU; Rab5a #1, GCUAUGAACG
UGAAUGAUCUU; Rab5a #2, CAAGCCUGGUAUUACGUUUUU;
Rab5a #3, ACAAACGUAUGGUGGAGUAUU; Rab11b #1, GACAGA
AGCCCAACAAGCUUU; Rab11b #2, GGAUUCCACUAACGUAGA
GUU; Rab11b #3, UAACGUAGAGGAAGCAUUCUU; Rab21 #1,
GGAGAGACAUGUUUCCAUUUU; Rab21 #2, GAGUAAACCUUGC
CAUAUGUU; Rab21 #4, CAAGAGAGAUUCCAUGCAUUU; Cdc42
#1, GUGGGUGCCUGAGAUAACUUU; Cdc42 #2, AGACUCCUUUC
UUGCUUGUUU; Integrin a5 #1, GAACGAGUCAGAAUUUCGA
UU; Integrin a5 #2, CAAACGCUCCCUCCCAUAUUU; RabGGTaseb
smart pool #M-007262-01; Rab4a smart pool #M-008539–01;
Rab4b smart pool #M-008780-03; Rab5a smart pool #M-004009-
00; Rab5b smart pool #M-004010-01; Rab8a smart pool #M-
003905-00; Rab8b smart pool #M-008744-01; Rab11a smart pool
#M-004726-02; Rab11b smart pool #M-004727-02; Rab21 smart
pool #M-009450-01.
Compound screening
The ‘library’ of compounds for screening is described with
Supplementary Table 1. A total of 2.5 10
3 CAFs were embedded
in 1ml of a mixture of collagen I and Matrigel yielding a final
collagen I concentration of approximately 4.6mgml
 1 and a final
Matrigel concentration of 2.2mgml
 1. Gel mix (100ml) per well
was plated in a 96-well plate. After the gel was set at 371C for 1h,
100ml media containing inhibitors or growth factors (see above)
were added on top of the gel at either 1 or 10mM final
concentration for 4 days with 100ml top up after 2 days. After
4 days, the plates were scanned and the diameter of the gel to well
was measured using ImageJ software (http://rsbweb.nih.gov/ij/).
The extent of contraction was assessed by subtracting the gel area
from the well area. For each plate, the contraction values were
normalised to the average contraction in the eight DMSO wells.
Microscopy
Cells were either plated on glass coverslips or seeded into a gel
consisting of 2–2.5mgml
 1 (BD Biosciences; catalogue no. 354234)
Matrigel and 4.25–4.75mgml
 1 collagen I (BD Biosciences;
catalogue no. 354249). Cells were fixed using 4% paraformaldehyde
in PBS and then permeablised using 0.25% Triton X-100 in PBS
before blocking with 3% bovine serum albumin in PBS. The
following primary antibodies were used diluted 1:100: anti-pS19-
MLC2 (Cell Signaling; catalogue no. 3671), anti-a5i n t e g r i n( S a n t a
Cruz; catalogue no. sc-13547), anti-Rab5a (Abcam; catalogue no.
ab18211). Fluorescent time-lapse imaging used MARS-lifeact (Riedl
et al, 2008) to highlight F-actin and CFP-Rab21. All fluorescent
images were acquired using Zeiss LSM 510 confocal microscopes
(Jena, Germany).
Organotypic invasion assays
Two types of organotypic assay were performed: either both cell
types were alive simultaneously as described in Gaggioli et al
(2007), or to more specifically evaluate the effect of compounds on
either the CAFs or the carcinoma cells, the assay was divided into
two phases. During the first phase CAFs were allowed 90–96h to
remodel the matrix in the absence of SCC12 cells before killing
with 10mgml
 1 puromycin. During this phase the matrix can be
remodelled by fibroblasts leading to its contraction: at the start of
the puromycin treatment the matrix was photographed to enable
quantification of the extent of contraction. After extensive washing
of the ECM with media for 24h SCC12, cells were plated on top of
the matrix that was mounted on a bridge at a gas/liquid interface
and left for 5 days. Inhibitors could be added during either phase.
Also all siRNA experiments were performed using this two-phase
experimental design.
Western blotting
Western blots were performed using standard techniques. The
following antibodies were used: Rab5a (Abcam; catalogue no.
ab18211), Rab21 (Santa Cruz; catalogue no. sc-81917), RabGGTa-
seb subunit (Abnova; catalogue no. h00005876-mo2), integrin a5
(Santa Cruz; catalogue no. sc-10729), pS19-MLC2 Cell Signaling
(catalogue no. 3671) and MLC Cell Signaling (catalogue no. 3672).
Adhesion assays
Adhesion assays were performed as described by Pinner and
Sahai (2008).
Flow cytometry
Analysis was performed as described by Brockbank et al (2005)
using anti-a5 integrin (Santa Cruz; catalogue no. sc-13547) on
non-permeablised cells.
RESULTS
A chemical screen identifies statins as reducing matrix
remodelling
Our previous work had shown a correlation between microscopic
matrix remodelling and macroscopic gel contraction (Gaggioli
et al, 2007). Further analysis showed a positive correlation between
matrix contraction by CAFs and their ability to promote SCC
invasion (Supplementary Figure 1). This led us to speculate that
compounds that block matrix contraction would also block
carcinoma cell invasion promoted by CAFs. To test this idea, we
developed a high-throughput assay for matrix contraction.
Carcinoma-associated fibroblasts consistently contract a collagen/
Matrigel matrix in a 96-well plate over a 4-day period. Matrix
contraction is blocked by a ROCK inhibitor, Y27632, which
reduces actomyosin contraction (Figure 1A). This effect was
simply quantified by measuring the area of the gel (Figure 1B).
We used 96-well plate assay to screen 182 inhibitors, growth
factors and cytokines for their ability to modulate collagen con-
traction at both 1 and 10mM. The screen was performed twice and
for each plate the matrix contraction was normalised to
the average of the DMSO control points before the average of
the two experiments was calculated. There were also 20 empty
wells included in the screening plates and from these we estimated
the normalised standard deviation of the assay as 0.08. Figure 1C, i
and ii shows the range of normalised scores following both 1 and
10mM treatment. A smaller range of deviation from the controls
was observed following 1mM treatment; although several com-
pounds reduced collagen contraction at both concentrations
(Figure 1C, iii). Compounds that reduced contraction to less than
0.6 at 1mM also reduced contraction at 10mM but that the converse
was not necessarily true. The complete data set is listed in Supple-
mentary Table 1; whereas selected classes of compounds are shown
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sin Figure 1C, iv. Four out of the five compounds included in
the screen reported to inhibit ROCK1 and 2 strongly reduced
collagen contraction (including the well-established ROCK inhi-
bitors Y27632 and H1152). The broad-spectrum MMP inhibitor
GM6001 also inhibited matrix contraction. Interestingly, two
HMG-CoA reductase inhibitors (simvastatin and lovastatin,
generically referred to as statins) reduced collagen contraction
by B0.4 and B0.1 normalised units at 10 and 1mM respectively
(highlighted with red arrowheads in Figure 1C, iv). Statins are
widely used to treat hypercholesterolaemia and have been asso-
ciated with reduced cancer incidence and/or mortality (Demierre
et al, 2005). We therefore decided to investigate their action on
matrix remodelling by CAFs further.
We confirmed that the defects in collagen contraction observed
macroscopically reflected defects in matrix re-organisation at the
microscopic level. Control and DMSO-treated fibroblasts were
able to both locally concentrate matrix (increased green signal
around cells) and generate large holes (dark areas) in the matrix
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Figure 1 Chemical screen to identify compounds that block fibroblast-promoted matrix remodeling. (A) Replicates are shown of CAFs contracting ECM
over a 4-day period in 96-well plates in the absence or presence of 10mM Y27632. (B) Quantification of the gel area of eight replicates of the gel contraction
assay ±10mM Y27362. The dotted line represents the area of the well, which is equivalent to the gel area at the start of the assay. (C) (i) Range of
normalised gel contraction values is shown following 10mM treatment of CAFs for 4 days. Median¼1.002; mean¼0.979 and standard deviation¼0.080 for
empty control wells. (ii) Range of normalised gel contraction values is shown following 1mM treatment of CAFs for 4 days. (iii) Range of normalised gel
contraction values is shown along the x axis following 10mM treatment (blue) of CAFs for 4 days together with the extent of gel contraction following 1mM
treatment with same compound (pink). (iv) Range of normalised gel contraction values is shown following 10mM treatment of CAFs for 4 days with selected
classes of compounds highlighted. (D) Reflectance images of the extracellular matrix (green) and carcinoma-associated fibroblasts (F-actin staining in red) are
shown. Cultures were treated with DMSO, 1mM simvastatin or 1mM lovastatin for 48h.
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s(Figure 1D). In contrast, these activities were defective in
simvastatin- or lovastatin-treated fibroblasts. We next tested
whether statins affect CAF-promoted SCC invasion. Figure 2A
shows that both statins reduce SCC invasion in an organotypic
model with IC50 values approximately 0.5–1mM. Supplementary
Figure 2 shows that neither cell growth nor survival was
significantly affected by statin doses below 5mM. The organotypic
assay used to assess invasion depends on two cell types, the SCC
cells and CAFs, either one of which could be affected by statin
treatment. To determine which cell type is critically affected by
statins, we used a modified assay in which fibroblast-mediated
matrix remodelling and SCC invasion into the matrix occur
sequentially (Gaggioli et al, 2007). Statins were then applied either
during the fibroblast-promoted matrix remodelling phase or the
SCC invasion phase when carcinoma cells move into a matrix that
has previously been ‘conditioned’ by CAFs. Figure 2B and C shows
that 1mM simvastatin or lovastatin treatment during the matrix
remodelling phase reduces SCC invasion but treatment after this
phase has no effect. These data indicate that statins prevent CAFs
from generating a matrix that is permissive for SCC invasion and
not by preventing SCC cells invading an already permissive matrix.
Rab protein lipid modification is required for matrix
remodelling
Statins modulate cholesterol biosynthesis indirectly and also affect
the production of many other metabolites (Werner et al, 2002;
Walker and Olson, 2005). In particular, the biosynthesis of
mevalonate, geranyl-, farnesyl- and geranylgeranyl-pyrophosphate
is affected by statin treatment. To investigate the mechanism of
statin action in more detail, we attempted to ‘rescue’ the effect of
statin treatment by adding additional mevalonate or geranylger-
anyl-pyrophosphate. As expected, mevalonate restored both
matrix contraction by CAFs and their ability to generate matrix
permissive for SCC12 invasion (Figure 2D and E). In addition,
geranylgeranyl-pyrophosphate significantly restored these activ-
ities in CAFs (Figure 2D and E). This finding is striking because
geranylgeranyl-pyrophosphate is not an intermediate between
HMG-CoA reductase and cholesterol synthesis but is largely used
to modify small G proteins and enable their interaction with
cellular membranes. Furthermore, previous reports have docu-
mented defects in small G-protein targeting after statin treatment
(Laezza et al, 1998; Kusama et al, 2001; Holstein et al, 2002;
Ghittoni et al, 2005; Walker and Olson, 2005). In agreement with
these findings, simvastatin and lovastatin both affected the
subcellular localisation of a range of small G proteins in CAFs
(Figure 3A and B). Of the proteins investigated, the subcellular
targeting of Rab5 and RhoA was most sensitive to statin treat-
ment with pronounced effects observed at doses that also reduce
fibroblast-stimulated SCC invasion (1mM). We have previously
shown a role for RhoA in matrix remodelling by CAFs (Gaggioli
et al, 2007) but were intrigued by the possibility that Rab proteins
may also be critical for this process.
To test whether the geranylgeranyl modification of Rab proteins
is required for CAFs to promote SCC invasion, we depleted the
enzyme that adds the lipid groups to Rab proteins. Two
independent siRNA to the RabGGTaseb subunit effectively
depleted that protein and also prevented fibroblasts from
contracting the ECM (Figure 3C and D). Furthermore, siRNA
against RabGGTaseb subunit dramatically reduced the ability of
CAFs to promote the invasion of SCC cells (Figure 3D). These data
show that lipid modification of Rab proteins is critical for CAF-
promoted cancer cell invasion. We next wished to determine which
Rabs might be required for CAFs to promote SCC invasion. We
therefore screened numerous Rabs that have been implicated in
cytoskeletal regulation, integrin or MMP trafficking. Figure 5A
shows that siRNA smart pools to Rab4b, Rab5a, Rab8a, Rab8b,
Rab11b and Rab21 reduced the ability of CAFs to contract the ECM
(Figure 4A). Correspondingly, all these Rabs except Rab4a reduced
CAF-promoted SCC invasion (Figure 4B). The results for
Rab5a, Rab11b and Rab21 could be reproduced using at least
three independent siRNA targeting sequences (Figure 4C, i). The
efficiency of siRNA knockdown of Rab5a and Rab21 is shown
in Figure 4C, ii and iii. Interestingly, depletion of Rab5a, 11b or 21
in carcinoma cells did not affect their ability to invade into matrix
that had previously been remodelled by fibroblasts (Figure 4D).
Rab21 is required for integrin a5 accumulation at the
plasma membrane
Rab5a, 11 and 21 have all been implicated in the recycling of
integrins, although Rab11 is implicated in a different recycling
route from Rabs5a and 21 (Jones et al, 2006; Pellinen et al, 2006).
In agreement with this we found that there was extensive
colocalisation between Rab5a and Rab21 but not with Rab11b
(Supplementary Figure 3). To learn more about the role of these
Rabs, we performed time-lapse imaging of control and Rab-
depleted CAFs plated on deformable collagen-rich matrices. Mock-
or control-transfected CAFs exhibited broad cell protrusions that
were either associated with cell motility or local deformation of the
matrix (Supplementary Movie 1). In contrast, Rab5a-, 11b- or 21-
depleted cells had more transient protrusions that were not usually
associated with matrix deformation or movement (Rab21siRNA
shown in Supplementary Movie 2). To determine if depletion of
Rab5a, Rab11b or Rab21 was simply preventing fibroblasts from
adhering to the matrix, we performed cell adhesion assays.
Adhesion to the collagen I/Matrigel mixture used in our assays
was reduced to varying degrees by depletion of Rab GGTaseb,
Rab11b and Rab5a, and by an integrin b1 blocking antibody
(Figure 5A). Interestingly, siRNA against Rab21 had no effect:
therefore, defects in matrix remodelling in the absence of Rab21
are not due to a failure to adhere to the ECM (Figure 5A). This led
us to focus our attention on Rab21. We confirmed that low doses
of statins disrupted the subcellular localisation of Rab21 (Supple-
mentary Figure 4).
We next investigated if Rab21 was having a more specific effect
on the cell adhesion machinery. Analysis of the location of a range
of integrins revealed that a fraction of integrin a5 colocalised with
Rab5a and Rab21 in fibroblasts in three-dimensional matrices
(Figure 5B). In many cases Rab21 appeared to be most
concentrated around the outside of the Rab5a- and integrin a5-
positive vesicles (in top part of panels, marked with arrowheads).
We therefore investigated if Rab5a or Rab21 were involved
regulating integrin a5 in CAFs. Depletion of Rab21 and, to a
lesser extent, Rab5a led to accumulation of integrin a5 in internal
vesicular structures with slightly lower levels of plasma membrane
staining (Figure 5C, marked with red arrowheads). We used
quantitative flow cytometry to confirm the reduction in integrin a5
levels at the plasma membrane following Rab21 depletion
(Figure 5D). In the absence of Rab21 integrin a5 accumulates in
intracellular vesicles positive for Rab5 (Figure 5E) and EE1A (data
not shown). Total integrin a5 levels were not significantly affected
by Rab21 siRNA (Figure 5E). We did not see any dramatic changes
in the distribution of integrin b1, a3o raV in Rab21-depleted cells
(Supplementary Figure 5), nor did we observe affects on cell
proliferation following Rab21 knockdown (Supplementary Figure
6A). Together these data suggest that Rab21 is required for
efficient delivery of integrin a5 to the plasma membrane.
ROCK-dependent regulation of actomyosin contractility is
critical for matrix remodelling (Figure 1; Gaggioli et al, 2007).
We therefore tested whether fibroblasts lacking Rab21 or integrin
a5 had defects in the activation of the actomyosin contrac-
tile machinery. Control cells typically had an elongated morpho-
logy with thick actin cables associated with phosphorylated ‘active’
MLC running along their length. Strikingly, cells depleted for
Rab21 had a less elongated morphology (quantification is shown in
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Figure 2 Statins prevent fibroblasts from promoting the invasion of carcinoma cells. (A) Invasion of organotypic cultures of SCC12 cells overlaid on top of
a collagen-rich matrix containing CAFs (where indicated) were treated with the indicated dose of either simvastatin or lovastatin. The extent of SCC12
invasion is shown: values were normalised to the þCAF invasion index and the average of 10 fields from two experiments is shown. *Po0.01, Student’s
t-test. (B) Representative images showing SCC12 invasion into a collagen-rich matrix with either fibroblasts treated with 1mM lovastatin or simvastatin during
the CAF remodeling phase or SCC12 cells treated during the invasion phase of the assay. (C) CAFs were allowed to remodel a collagen-rich matrix before
they were killed and SCC12 cells were overlaid on the remodelled matrix. The indicated dose of simvastatin or lovastatin (mM) was added either during the
CAF remodeling phase (left-hand side) or during the SCC12 invasion phase (right-hand side). The extent of SCC12 invasion is shown: values were
normalised to the þCAF invasion index and the average of 10 fields from two experiments is shown. *Po0.01, Student’s t-test. (D) Matrix contraction by
CAFs after 4 days is shown following the indicated treatments (1mM simvastatin, 20mM GGPP, 400mM mevalonate). Numbers represent the decrease in area
of the matrix normalised to the control. (E) CAFs were allowed to remodel the matrix in the presence of the indicated treatments before they were killed
and SCC12 cells were overlaid on the remodelled matrix. The extent of SCC12 invasion is shown: values were normalised to the þCAF invasion index and
the average of 10 fields from two experiments is shown. *Po0.01, Student’s t-test.
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sSupplementary Figure 6B). Rab21-depleted cells also lacked contrac-
tile actomyosin cables spanning the cell body, although phosphory-
lated MLC could still be detected (Figure 6A). Fibroblasts depleted
for integrin a5 also had reduced levels of phosphorylated MLC
associated with F-actin cables. Western blot analysis confirmed that
Rab21 and integrin a5 regulate MLC phosphorylation in CAFs
(Figure 6B). We further probed the relationship between Rab21 and
cell contractility by analysing Rab21 dynamics in CAFs plated on
deformable matrices. Figure 6C shows that Rab21 is much more
prominently localised in areas of the cell that are contracting com-
pared to those that are protruding (also Supplementary Movie 3).
These data suggest that the localised delivery of Rab21 cargoes, such
as integrin a5, can promote the generation of contractile force.
To determine whether reduced integrin a5 function could
account for the reduced ability of Rab21-depleted CAFs to contract
the matrix and promote SCC invasion, we investigated the effect of
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Figure 3 Rab protein modification is a key target of statin action. (A) Images of GFP-Rab5 and GFP-RhoA localisation in CAFs are shown in the absence
or presence of 1mM simvastatin. (B) Quantification of the proportion of CAFs with correct subcellular targeting of mRFP-Cdc42 (plasma membrane),
GFP-RhoA (plasma membrane), GFP-Rab5a (endosomal) and mRFP-K-ras C-term (plasma membrane) at the indicated doses of lovastatin or simvastatin.
(C) Western blot showing levels of RabGGTaseb subunit following transfection of smart-pool siRNAs # 1 and # 2 targeting RabGGTaseb subunit.
b-Tubulin is shown as a loading control. (D) (i) Matrix contraction by CAFs after 4 days is shown following transfection of smart-pool siRNAs #1 and #2
targeting RabGGTaseb subunit. (ii) CAFs were allowed to remodel a collagen-rich matrix following transfection of smart-pool siRNAs #1 and #2 targeting
RabGGTaseb subunit before they were killed and SCC12 cells were overlaid on the remodelled matrix. The extent of SCC12 invasion is shown: values were
normalised to the þCAF invasion index and the average of 10 fields from two experiments is shown. *Po0.01, Student’s t-test.
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Figure 4 Rabs 5a, 11b and 21 are required for fibroblasts to promote SCC invasion. (A) Matrix contraction by CAFs after 4 days is shown following
transfection of smart-pool siRNAs against the Rabs indicated. (B) CAFs were allowed to remodel a collagen-rich matrix following transfection of smart-pool
siRNAs against the Rabs indicated before they were killed and SCC12 cells were overlaid on the remodelled matrix. The extent of SCC12 invasion is shown:
values were normalised to the þCAF invasion index and the average of 10 fields from two experiments is shown, error bars represent half range of the data.
*Po0.01, Student’s t-test. (C) (i) CAFs were allowed to remodel the matrix following transfection of single siRNAs against the Rabs indicated
before they were killed and SCC12 cells were overlaid on the remodelled matrix. The extent of SCC12 invasion is shown: values were normalised to the
þCAF invasion index and the average of 10 fields from two experiments is shown, error bars represent half range of the data. *Po0.01, Student’s t-test.
(ii) Western blot showing levels of Rab5a following transfection of siRNAs #1, #2 and #3 targeting Rab5a. b-Tubulin is shown as a loading control.
(iii) Western blot showing levels of Rab21 following transfection of siRNAs #1, #2 #3 and #4 targeting Rab21. b-Tubulin is shown as a loading
control. (D) Invasion of SCC12 cells following transfection of single siRNAs against the Rabs indicated (or Cdc42) into a CAF-conditioned matrix is shown.
Invasion index is relative to untreated controls. Average of 10 fields from two experiments is shown, error bars represent half range of the data. *Po0.01,
Student’s t-test.
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sintegrin a5 depletion. Figure 7A shows that depletion of integrin a5
reduces matrix contraction by CAFs (efficacy of siRNAs #1 and 2
shown in Figure 6A). Correspondingly, integrin a5 depletion also
reduces the ability of CAFs to promote SCC invasion (Figure 7B).
These data support integrin a5 delivery to the plasma membrane as
a key function of Rab21 in enabling CAF-promoted SCC invasion.
DISCUSSION
Matrix remodelling by fibroblasts is critical for normal and patho-
logical processes including wound healing, fibrosis and cancer
invasion (Grinnell, 2003). One manifestation of matrix remodelling
is contraction of collagen gels (Ngo et al, 2006). We noted a
correlation between CAF-promoted matrix contraction and their
ability to promote the invasion of carcinoma cells. Therefore, we
screened B200 compounds to identify agents that would prevent
matrix contraction with the hope that they would also reduce
fibroblast-promoted carcinoma invasion. Numerous compounds
were identified in this screen; however, many were discarded when
we tested their effect on cell viability. We also noticed that many
compounds that reportedly have the same molecular target gave
different matrix contraction scores (Supplementary Table 1). This
may reflect differing stabilities of the compounds in the 4-day
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Figure 5 Rab21 is required for integrin a5 to exit Rab5-positive vesicles. (A) CAF adhesion to a mixture of collagen I/Matrigel is shown following
transfection of smart-pool siRNAs against the Rabs indicated or incubation with integrin b1 blocking antibody, AIIB2. Average of six fields from two
experiments is shown, error bars represent half range of the data. *Po0.01, Student’s t-test; ~Po0.05, Student’s t-test. (B) Localisation of CFP-Rab21
(green in merge), endogenous Rab5a (blue in merge) and endogenous integrin a5 (red in merge) in a CAF cultured within a three-dimensional matrix of
collagen I/Matrigel. Scale bar¼10mm. (C) Localisation of integrin a5 in CAFs following transfection of smart-pool siRNAs against the Rabs indicated. Red
arrowheads indicate intracellular vesicles. (D) Flow cytometry analysis of integrin a5 levels on the surface of CAFs following transfection of siRNA targeting
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smatrix contraction assay, varying degrees of efficacy or off-target
effects.
We focused on two related agents that scored similarly in the
matrix contraction assay, simvastatin and lovastatin. As we
hypothesised, these compounds also reduced the ability of CAFs
to promote cancer cell invasion. Statins are of interest because
several studies have shown reduced cancer incidence or mortality
in patients taking these drugs for elevated cholesterol (Demierre
et al, 2005). Several mechanisms have been put forward to account
for these observations (Murtola et al, 2008). Here, we show that
statins reduce cancer invasion by targeting the stromal compart-
ment. Specifically, statins reduce the ability of CAFs to remodel the
matrix in a way that enables carcinoma cell invasion. Importantly,
this effect occurs at doses (0.5 and 1mM) that are not cytotoxic or
cytostatic and are close to those observed in cancer patients
(Holstein et al, 2006). Consistent with this, statins can reduce the
activation of other types of fibroblast and matrix contraction
(Meyer-Ter-Vehn et al, 2008; Burke et al, 2009), although Rab
proteins were not implicated. This suggests reduced matrix
remodelling by the stroma could partly account for the altered
cancer incidence in people taking statins. However, this study does
not exclude other mechanisms.
Further analysis led us to conclude that cholesterol is not the
critical target involved in matrix remodelling but to focus on proteins
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Figure 6 Rab21 and integrin a5 are required for actomyosin cables. (A) Panels show the organisation of integrin a5 (blue in merge), F-actin (red in
merge) and pS19-MLC (green in merge) in CAFs plated on a mixture of collagen I/Matrigel. Scale bar¼20mm. (B) Western blots show pS19-MLC and total
MLC levels in CAFs plated on collagen-rich gels following transfection of siRNA targeting Rab21 or integrin a5. (C) Left-hand panel shows the actin
organisation in a CAF plated on a mixture of collagen I/Matrigel at two time points 3min apart (t¼0 is in red and t¼3 is in green). Areas of protrusion and
retraction are indicated. Right-hand panel shows the distribution of actin (red) and Rab21 (green) in the same cell at t¼0. Scale bar¼10mm.
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sthat have GGPP modifications. At least three Rab proteins (5a, 11b
and 21) are required in CAFs for their ability to promote SCC
invasion. Depletion of these Rabs did not affect the ability of SCC
cells to invade matrix that had previously been remodelled by CAFs;
this is probably because the ‘following’ SCC cells do not remodel the
ECM and therefore matrix remodelling pathways are dispensable in
SCC cells. Subsequent experiments showed that Rab21 is specifically
required for effective integrin a5 accumulation at the plasma
membrane. When Rab21 is absent, integrin a5 accumulates in
Rab5a-positive vesicles suggesting that Rab21 is required for exit
from this compartment (Figure 7C). Provocatively, Rab21-positive
vesicles are preferentially localised to areas of cell contraction and
both Rab21 and integrin a5 are needed for MLC phosphorylation.
These data led us to propose that Rab21 delivers integrin a5t o
the plasma membrane where it locally signals to the contractile
machinery. Interestingly, a connection between Rab21, integrins
and actomyosin regulation has been reported during cytokinesis
(Pellinen et al, 2006, 2008). This is probably through the activation
of Rho–ROCK function as ligand-bound integrin a5 can signal to
RhoGEFs and thereby increase Rho activity (Ren et al, 1999; Dubash
et al, 2007; Huveneers et al,2 0 0 8 ) .I n t e g r i na5 has also been
implicated in collagen gel contraction in other fibroblast types (Liu
et al, 2006). In these experiments it appears that other integrins are
unable to compensate for loss of integrin a5 function. Our data do
not exclude the possibility that Rab21 is required for the delivery or
trafficking of other critical targets, in addition to integrin a5.
The analysis performed here illustrates that targeting of the stroma
alone can reduce the invasion of cancer cells. Unfortunately, it also
implies that the implementation of anti-invasion agents that target
matrix remodelling may only be of limited use if the matrix
surrounding a tumour is already permissive for carcinoma invasion.
Nonetheless, statins may be useful in slowing the progression of early
stage lesions and in range of other pathologies associated with
aberrant fibroblast-mediated matrix remodelling, such as scarring and
fibrosis. In conclusion, we have shown the feasibility of intermediate-
to high-throughput screening of compounds that block matrix
remodelling by fibroblasts. Following on from this, we have shown
that statins reduce SCC invasion by targeting matrix remodelling by
CAFs and have uncovered a critical role for Rab21 in this process.
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